Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 27.9% during trading on Friday . The company traded as high as C$0.29 and last traded at C$0.28. 1,401,717 shares traded hands during trading, an increase of 100% from the average session volume of 700,531 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Performance
The firm has a market capitalization of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20. The firm’s 50-day moving average price is C$0.10 and its two-hundred day moving average price is C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Investors Need to Know About Upcoming IPOs
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
